BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for severe aplastic anemia (SAA). However, graft failure and graft-versus-host disease (GVHD) are major causes of the early morbidity in Allo-HSCT. METHODS: To reduce graft failure and GVHD, we treated fifteen patients with SAA using high- dose of HSCT with both G-CSF mobilized PB and BMSCs from HLA-identical siblings to treat patients with SAA. RESULTS: All patients had successful bone marrow engraftment. Only one patient had late rejection. Median time to ANC greater than 0.5 × 10(9)/L and platelet counts greater than 20 × 10(9)/L was 12 and 16.5 days, respectively. No acute GVHD was observed. The incidence of chronic GVHD was 6.67%. The total three-year probability of disease-free survival was 79.8%. CONCLUSION: HSCT with both G-CSF mobilized PB and BMSCs is a promising approach for heavily transfused and/or allo-immunized patients with SAA.
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for severe aplastic anemia (SAA). However, graft failure and graft-versus-host disease (GVHD) are major causes of the early morbidity in Allo-HSCT. METHODS: To reduce graft failure and GVHD, we treated fifteen patients with SAA using high- dose of HSCT with both G-CSF mobilized PB and BMSCs from HLA-identical siblings to treat patients with SAA. RESULTS: All patients had successful bone marrow engraftment. Only one patient had late rejection. Median time to ANC greater than 0.5 × 10(9)/L and platelet counts greater than 20 × 10(9)/L was 12 and 16.5 days, respectively. No acute GVHD was observed. The incidence of chronic GVHD was 6.67%. The total three-year probability of disease-free survival was 79.8%. CONCLUSION: HSCT with both G-CSF mobilized PB and BMSCs is a promising approach for heavily transfused and/or allo-immunized patients with SAA.
Authors: M Remberger; N Naseh; J Aschan; L Barkholt; K LeBlanc; P Svennberg; O Ringdén Journal: Bone Marrow Transplant Date: 2003-07 Impact factor: 5.483
Authors: B S Cho; K S Eom; Y J Kim; H J Kim; S Lee; C K Min; S G Cho; W S Min; C W Park; C C Kim; J W Lee Journal: Bone Marrow Transplant Date: 2010-01-11 Impact factor: 5.483
Authors: Jonathan A Storey; Rebecca F Connor; Zachary T Lewis; David Hurd; Gregory Pomper; Yi K Keung; Manisha Grover; James Lovato; Suzy V Torti; Frank M Torti; István Molnár Journal: J Hematol Oncol Date: 2009-10-24 Impact factor: 17.388
Authors: Jessica A Schuster; Maria R Stupnikov; Gina Ma; Wenbin Liao; Raymond Lai; Yupo Ma; Jerell R Aguila Journal: Exp Hematol Oncol Date: 2012-05-14